431 related articles for article (PubMed ID: 22508825)
1. Cladribine, but not fludarabine, added to daunorubicin and cytarabine during induction prolongs survival of patients with acute myeloid leukemia: a multicenter, randomized phase III study.
Holowiecki J; Grosicki S; Giebel S; Robak T; Kyrcz-Krzemien S; Kuliczkowski K; Skotnicki AB; Hellmann A; Sulek K; Dmoszynska A; Kloczko J; Jedrzejczak WW; Zdziarska B; Warzocha K; Zawilska K; Komarnicki M; Kielbinski M; Piatkowska-Jakubas B; Wierzbowska A; Wach M; Haus O
J Clin Oncol; 2012 Jul; 30(20):2441-8. PubMed ID: 22508825
[TBL] [Abstract][Full Text] [Related]
2. Daunorubicin, cytarabine and fludarabine (DAF) for remission induction in relapsed or refractory acute myeloid leukemia. Evaluation of safety, tolerance and early outcome--Polish Adult Leukemia Group (PALG) pilot study.
Hołowiecki J; Grosicki S; Kyrcz-Krzemien S; Skotnicki AB; Piatkowska-Jakubas B; Warzocha K; Seferynska I; Zdziarska B
Ann Hematol; 2008 May; 87(5):361-7. PubMed ID: 18074133
[TBL] [Abstract][Full Text] [Related]
3. Addition of cladribine to daunorubicin and cytarabine increases complete remission rate after a single course of induction treatment in acute myeloid leukemia. Multicenter, phase III study.
Holowiecki J; Grosicki S; Robak T; Kyrcz-Krzemien S; Giebel S; Hellmann A; Skotnicki A; Jedrzejczak WW; Konopka L; Kuliczkowski K; Zdziarska B; Dmoszynska A; Marianska B; Pluta A; Zawilska K; Komarnicki M; Kloczko J; Sulek K; Haus O; Stella-Holowiecka B; Baran W; Jakubas B; Paluszewska M; Wierzbowska A; Kielbinski M; Jagoda K;
Leukemia; 2004 May; 18(5):989-97. PubMed ID: 14999298
[TBL] [Abstract][Full Text] [Related]
4. Infectious complications in patients with acute myeloid leukemia treated according to the protocol with daunorubicin and cytarabine with or without addition of cladribine. A multicenter study by the Polish Adult Leukemia Group (PALG).
Lech-Maranda E; Seweryn M; Giebel S; Holowiecki J; Piatkowska-Jakubas B; Wegrzyn J; Skotnicki A; Kielbinski M; Kuliczkowski K; Paluszewska M; Jedrzejczak WW; Dutka M; Hellmann A; Flont M; Zdziarska B; Palynyczko G; Konopka L; Szpila T; Gawronski K; Sulek K; Sokolowski J; Kloczko J; Warzocha K; Robak T
Int J Infect Dis; 2010 Feb; 14(2):e132-40. PubMed ID: 19581118
[TBL] [Abstract][Full Text] [Related]
5. Addition of cladribine to the standard induction treatment improves outcomes in a subset of elderly acute myeloid leukemia patients. Results of a randomized Polish Adult Leukemia Group (PALG) phase II trial.
Pluta A; Robak T; Wrzesien-Kus A; Katarzyna Budziszewska B; Sulek K; Wawrzyniak E; Czemerska M; Zwolinska M; Golos A; Holowiecka-Goral A; Kyrcz-Krzemien S; Piszcz J; Kloczko J; Mordak-Domagala M; Lange A; Razny M; Madry K; Wiktor-Jedrzejczak W; Grosicki S; Butrym A; Kuliczkowski K; Warzocha K; Holowiecki J; Giebel S; Szydlo R; Wierzbowska A
Am J Hematol; 2017 Apr; 92(4):359-366. PubMed ID: 28103640
[TBL] [Abstract][Full Text] [Related]
6. 6-Thioguanine, cytarabine, and daunorubicin (TAD) and high-dose cytarabine and mitoxantrone (HAM) for induction, TAD for consolidation, and either prolonged maintenance by reduced monthly TAD or TAD-HAM-TAD and one course of intensive consolidation by sequential HAM in adult patients at all ages with de novo acute myeloid leukemia (AML): a randomized trial of the German AML Cooperative Group.
Büchner T; Hiddemann W; Berdel WE; Wörmann B; Schoch C; Fonatsch C; Löffler H; Haferlach T; Ludwig WD; Maschmeyer G; Staib P; Aul C; Gruneisen A; Lengfelder E; Frickhofen N; Kern W; Serve HL; Mesters RM; Sauerland MC; Heinecke A;
J Clin Oncol; 2003 Dec; 21(24):4496-504. PubMed ID: 14673036
[TBL] [Abstract][Full Text] [Related]
7. Improved outcome in pediatric relapsed acute myeloid leukemia: results of a randomized trial on liposomal daunorubicin by the International BFM Study Group.
Kaspers GJ; Zimmermann M; Reinhardt D; Gibson BE; Tamminga RY; Aleinikova O; Armendariz H; Dworzak M; Ha SY; Hasle H; Hovi L; Maschan A; Bertrand Y; Leverger GG; Razzouk BI; Rizzari C; Smisek P; Smith O; Stark B; Creutzig U
J Clin Oncol; 2013 Feb; 31(5):599-607. PubMed ID: 23319696
[TBL] [Abstract][Full Text] [Related]
8. Comparison of cladribine plus cyclophosphamide with fludarabine plus cyclophosphamide as first-line therapy for chronic lymphocytic leukemia: a phase III randomized study by the Polish Adult Leukemia Group (PALG-CLL3 Study).
Robak T; Jamroziak K; Gora-Tybor J; Stella-Holowiecka B; Konopka L; Ceglarek B; Warzocha K; Seferynska I; Piszcz J; Calbecka M; Kostyra A; Dwilewicz-Trojaczek J; Dmoszyñska A; Zawilska K; Hellmann A; Zdunczyk A; Potoczek S; Piotrowska M; Lewandowski K; Blonski JZ
J Clin Oncol; 2010 Apr; 28(11):1863-9. PubMed ID: 20212251
[TBL] [Abstract][Full Text] [Related]
9. A randomized, postremission comparison of four courses of standard-dose consolidation therapy without maintenance therapy versus three courses of standard-dose consolidation with maintenance therapy in adults with acute myeloid leukemia: the Japan Adult Leukemia Study Group AML 97 Study.
Miyawaki S; Sakamaki H; Ohtake S; Emi N; Yagasaki F; Mitani K; Matsuda S; Kishimoto Y; Miyazaki Y; Asou N; Matsushima T; Takahashi M; Ogawa Y; Honda S; Ohno R;
Cancer; 2005 Dec; 104(12):2726-34. PubMed ID: 16284985
[TBL] [Abstract][Full Text] [Related]
10. Addition of Cladribine to Idarubicin and Cytarabine during Induction Increases the Overall Efficacy Rate in Adult Patients with Acute Myeloid Leukemia: A Matched-Pair Retrospective Comparison.
Shen Y; Chen J; Liu Y; Wu D
Chemotherapy; 2014; 60(5-6):368-74. PubMed ID: 26496511
[TBL] [Abstract][Full Text] [Related]
11. Comparison of cladribine- and fludarabine-based induction chemotherapy in relapsed or refractory acute myeloid leukaemia.
Park H; Youk J; Kim I; Yoon SS; Park S; Lee JO; Bang SM; Koh Y
Ann Hematol; 2016 Oct; 95(11):1777-86. PubMed ID: 27539617
[TBL] [Abstract][Full Text] [Related]
12. Sequential continuous infusion of fludarabine and cytarabine associated with liposomal daunorubicin (DaunoXome) (FLAD) in primary refractory or relapsed adult acute myeloid leukemia patients.
Camera A; Rinaldi CR; Palmieri S; Cantore N; Mele G; Mettivier V; Miraglia E; Mastrullo L; Grimaldi F; Luciano L; Guerriero A; Rotoli B; Ferrara F
Ann Hematol; 2009 Feb; 88(2):151-8. PubMed ID: 18709502
[TBL] [Abstract][Full Text] [Related]
13. Optimization of chemotherapy for younger patients with acute myeloid leukemia: results of the medical research council AML15 trial.
Burnett AK; Russell NH; Hills RK; Hunter AE; Kjeldsen L; Yin J; Gibson BE; Wheatley K; Milligan D
J Clin Oncol; 2013 Sep; 31(27):3360-8. PubMed ID: 23940227
[TBL] [Abstract][Full Text] [Related]
14. [IDA-FLAG (idarubicin, fludarabine, high dosage cytarabine and G-CSF)--an effective therapy regimen in treatment of recurrent acute myelocytic leukemia in children and adolescents. Initial results of a pilot study].
Fleischhack G; Graf N; Hasan C; Ackermann M; Breu H; Zernikow B; Bode U
Klin Padiatr; 1996; 208(4):229-35. PubMed ID: 8926688
[TBL] [Abstract][Full Text] [Related]
15. A randomized trial of liposomal daunorubicin and cytarabine versus liposomal daunorubicin and topotecan with or without thalidomide as initial therapy for patients with poor prognosis acute myelogenous leukemia or myelodysplastic syndrome.
Cortes J; Kantarjian H; Albitar M; Thomas D; Faderl S; Koller C; Garcia-Manero G; Giles F; Andreeff M; O'Brien S; Keating M; Estey E
Cancer; 2003 Mar; 97(5):1234-41. PubMed ID: 12599230
[TBL] [Abstract][Full Text] [Related]
16. High-dose cytarabine in induction treatment improves the outcome of adult patients younger than age 46 years with acute myeloid leukemia: results of the EORTC-GIMEMA AML-12 trial.
Willemze R; Suciu S; Meloni G; Labar B; Marie JP; Halkes CJ; Muus P; Mistrik M; Amadori S; Specchia G; Fabbiano F; Nobile F; Sborgia M; Camera A; Selleslag DL; Lefrère F; Magro D; Sica S; Cantore N; Beksac M; Berneman Z; Thomas X; Melillo L; Guimaraes JE; Leoni P; Luppi M; Mitra ME; Bron D; Fillet G; Marijt EW; Venditti A; Hagemeijer A; Mancini M; Jansen J; Cilloni D; Meert L; Fazi P; Vignetti M; Trisolini SM; Mandelli F; de Witte T
J Clin Oncol; 2014 Jan; 32(3):219-28. PubMed ID: 24297940
[TBL] [Abstract][Full Text] [Related]
17. Acute Myeloid Leukemia (AML): different treatment strategies versus a common standard arm--combined prospective analysis by the German AML Intergroup.
Büchner T; Schlenk RF; Schaich M; Döhner K; Krahl R; Krauter J; Heil G; Krug U; Sauerland MC; Heinecke A; Späth D; Kramer M; Scholl S; Berdel WE; Hiddemann W; Hoelzer D; Hehlmann R; Hasford J; Hoffmann VS; Döhner H; Ehninger G; Ganser A; Niederwieser DW; Pfirrmann M
J Clin Oncol; 2012 Oct; 30(29):3604-10. PubMed ID: 22965967
[TBL] [Abstract][Full Text] [Related]
18. Induction of Acute Myeloid Leukemia with Idarubicin, Cytarabine and Cladribine.
Wiedower E; Jamy O; Martin MG
Anticancer Res; 2015 Nov; 35(11):6287-90. PubMed ID: 26504064
[TBL] [Abstract][Full Text] [Related]
19. Liposomal daunorubicin versus standard daunorubicin: long term follow-up of the GIMEMA GSI 103 AMLE randomized trial in patients older than 60 years with acute myelogenous leukaemia.
Latagliata R; Breccia M; Fazi P; Iacobelli S; Martinelli G; Di Raimondo F; Sborgia M; Fabbiano F; Pirrotta MT; Zaccaria A; Amadori S; Caramatti C; Falzetti F; Candoni A; Mattei D; Morselli M; Alimena G; Vignetti M; Baccarani M; Mandelli F
Br J Haematol; 2008 Dec; 143(5):681-9. PubMed ID: 18950458
[TBL] [Abstract][Full Text] [Related]
20. Phase III open-label randomized study of cytarabine in combination with amonafide L-malate or daunorubicin as induction therapy for patients with secondary acute myeloid leukemia.
Stone RM; Mazzola E; Neuberg D; Allen SL; Pigneux A; Stuart RK; Wetzler M; Rizzieri D; Erba HP; Damon L; Jang JH; Tallman MS; Warzocha K; Masszi T; Sekeres MA; Egyed M; Horst HA; Selleslag D; Solomon SR; Venugopal P; Lundberg AS; Powell B
J Clin Oncol; 2015 Apr; 33(11):1252-7. PubMed ID: 25732165
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
